Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pacmilimab - CytomX Therapeutics

Drug Profile

Pacmilimab - CytomX Therapeutics

Alternative Names: CX-072; PD-L1 probody therapeutic - CytomX Therapeutics

Latest Information Update: 21 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytomX Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Solid tumours
  • Phase I/II Lymphoma

Most Recent Events

  • 06 Oct 2021 CytomX Therapeutics completed the phase I/II trial in Solid tumours and Lymphoma (Monotherapy, Combination therapy, Metastatic disease, Late-stage disease, Recurrent, Unresectable/Inoperable, Second-line therapy or greater) in USA, Netherlands, Ukraine, United Kingdom, Poland, Hungary and Spain (NCT03013491) (EudraCT2016-002490-36)
  • 04 Aug 2021 Pharmacodynamics and pharmacokinetics data from preclinical studies in solid tumours released by CytomX Therapeutics
  • 04 Aug 2021 Updated efficacy and adverse events data from the phase I/IIa PROCLAIM-072 trial in Solid tumours released by CytomX Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top